Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
about
The host immune dynamics of pneumococcal colonization: implications for novel vaccine developmentIntranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine.An evaluation of emerging vaccines for childhood pneumococcal pneumonia.Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants.Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.Next generation protein based Streptococcus pneumoniae vaccinesEfficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children.Experience with pneumococcal conjugate vaccine in Norway.Carbohydrate-based vaccines: challenges and opportunities.Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.Designing a new antifungal glycoconjugate vaccine.The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility.The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice.A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.Validation of the World Health Organization Enzyme-Linked Immunosorbent Assay for the Quantitation of Immunoglobulin G Serotype-Specific Anti-Pneumococcal Antibodies in Human Serum.
P2860
Q28084920-8B6E08B9-3FFC-40CB-BF6A-1715D4A373A8Q34484116-48C119D2-C2C9-437B-AC21-26BC554686E4Q35569198-0E210462-863D-4320-9D38-D40A2CD933BEQ35595931-826677CF-93CA-4494-9650-015F731B0AC0Q35867061-C6C641FE-3935-40B0-A0DC-73ACF0775111Q36170124-9C9FED14-AF3B-4961-9B23-D6CBBEB1ADBFQ36557966-0FE307C1-6956-470C-A893-FD6BA22C69C2Q36605149-A466F2C8-8D06-4929-B8C2-3AF95BE57311Q36713715-6B1BA812-F826-4DD5-85B5-777E34BEED97Q36849935-4AB06201-7E06-45A5-B79C-97788EE274FAQ36907321-4420998C-BC7E-4623-8F2E-26F92F199CDCQ37116534-BA6F6D59-6023-4B10-A37E-7F8B6D534CEAQ37130191-76C81575-CCBC-4145-A46F-7BA3029CF171Q37145037-5904C121-87CC-4D9D-ABB7-4317BD5FAE22Q37164724-F28DE746-5EA3-4A97-856B-5AB8327BDED6Q37386281-0D7D27A1-07F7-4CD7-B0EA-24F238ADDE3EQ37810597-53EFBBA8-9C2B-4CB3-9584-1FED0466D9E7Q37857254-8BE37847-B47E-471E-B1D7-71D7A6A24CDDQ38066728-6986306B-BA6B-4513-8DE0-BDAE2CD0DF6CQ38569828-9DCCFF48-EEFE-494B-9F42-D176D49670F0Q38913326-5DB9423A-6EA6-4DEC-A550-668A6B9D7C35Q38966471-6E2C1360-F15C-4F49-A4B9-9D9802D02AC3Q39278063-DCADB63C-1AAE-433F-A81C-0C7D5AFC7C00Q39770701-BD05FCF6-81C3-4D24-9119-AD21EF69AF54Q40291567-AF453BFF-F3F8-43E9-8988-4F858488F81BQ41649005-18AE944D-3C6D-45AD-931B-06A579752BB9
P2860
Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@ast
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@en
type
label
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@ast
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@en
prefLabel
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@ast
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@en
P1433
P1476
Immunogenicity, efficacy, safe ...... onjugate vaccines (1998-2006).
@en
P2093
Froukje Oosterhuis-Kafeja
Philippe Beutels
P304
P356
10.1016/J.VACCINE.2006.11.032
P407
P577
2006-12-04T00:00:00Z